HBV carriage in children born from HIV-seropositive mothers in Senegal: The need of birth-dose HBV vaccination.
Hepatitis B is a major public health problem in Senegal, a country with high prevalence and a transmission occurring mainly during infancy. Only, one 6-8 weeks vaccination campaign was initiated in 2005 and it was part of the expanded program of immunization. The aim of this study was to determine the prevalence of HBsAg in children born from HIV-seropositive mothers by using dried blood specimens. Specimens were collected between July 2007 and November 2012 from children aged 2-48 weeks in Dakar and decentralized sites working on HIV mother-to-child transmission prevention. HBsAg detection was performed using Architect HBsAg Qualitative II kit (Abbott Diagnostics, Ireland) and for all reactive samples confirmation was done using Architect HBsAg Qualitative II Confirmatory kit (Abbott Diagnostics, Ireland). Nine hundred thirty samples were collected throughout the country with 66% out of Dakar, the capital city. The median age was 20 weeks and 88% of children were less than 1 year of age with a sex ratio of 1.27 in favor of boys. HBsAg was detected in 28 cases giving a global prevalence of 3%. According to age, HBsAg prevalences were 5.1% for children less than 6 weeks, 4.1% and 4.6%, respectively, for those aged 12-18 weeks and 18-24 weeks of age. The HIV prevalence was 2.6% with no HIV/HBV co-infection. This study showed a high rate of HBV infection in children under 24 months, highlighting the need to promote birth-dose HBV vaccination as recommended by WHO.
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Sokhna Bousso
SB
Gueye
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Halimatou
H
Diop-Ndiaye
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Gora
G
Lo
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Sandrine
S
Mintsa
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Ibrahima
I
Guindo
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Aminata
A
Dia
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Amina
A
Sow-Sall
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Aissatou
A
Gaye-Diallo
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Souleymane
S
Mboup
Laboratoire Bactériologie-Virologie, CHU Le Dantec, Université Cheikh Anta Diop, Dakar-Sénégal, Dakar, Senegal.
Coumba
C
Touré-Kane
D002353:Carrier State / Q000453:epidemiology* / Q000517:prevention & control; D002675:Child, Preschool; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology* / Q000517:prevention & control; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006515:Hepatitis B virus / Q000302:isolation & purification*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D012675:Senegal / Q000453:epidemiology; D016036:Seroepidemiologic Studies; D014611:Vaccination / Q000706:statistics & numerical data*
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines
HBsAg; Senegal; dried blood specimens; immunization; infants